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Peroxisome proliferator-activated receptors (PPARs) are transcriptional factors involved in the regulation of insulin resistance and
adipogenesis. Cinnamon, a widely used spice in food preparation and traditional antidiabetic remedy, is found to activate PPARγ
and α, resulting in improved insulin resistance, reduced fasted glucose, FFA, LDL-c, and AST levels in high-caloric diet-induced
obesity (DIO) and db/db mice in its water extract form. In vitro studies demonstrate that cinnamon increases the expression of
peroxisome proliferator-activated receptors γ and α (PPARγ/α) and their target genes such as LPL, CD36, GLUT4, and ACO in
3T3-L1 adipocyte. The transactivities of both full length and ligand-binding domain (LBD) of PPARγ and PPARα are activated
by cinnamon as evidenced by reporter gene assays. These data suggest that cinnamon in its water extract form can act as a dual
activator of PPARγ and α, and may be an alternative to PPARγ activator in managing obesity-related diabetes and hyperlipidemia.
Copyright © 2008 Xiaoyan Sheng et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Obesity has become the most common metabolic disorder
in the world and is a major risk factor for insulin resistance
in the development of type 2 diabetes mellitus [1]. Per-
oxisome proliferator-activated receptors (PPARs) have been
recognized as therapeutic targets against dyslipidemia and
diabetes since their discovery in the early 1990s. PPARs
are ligand-activated nuclear hormone receptors that include
three isoforms: PPARα,P P A R γ,a n dP P A R δ/β.P P A R α is
expressed mostly in brown adipose tissue and liver, PPARγ
is mainly expressed in adipose tissue, while PPARδ/β is
expressed universally in many tissues [2]. Activation of
PPARα lowers plasma triglycerides and elevates plasma HDL
cholesterol levels [3], while the activation of PPARγ increases
insulin sensitivity and results in antidiabetic eﬀects [4].
Since PPARs play key roles in regulating carbohydrate and
lipid metabolism, most studies have been directed toward
developing synthetic PPAR ligands, and current therapeutic
strategies are also based on separate treatments of insulin
resistance and dyslipidaemia. Fibrates, the PPARα agonists,
are now recommended for the treatment of cardiovascular
disease and dyslipidemia [5]. Thiazolinediones (TZDs), the
PPARγ agonists, have been demonstrated by a number of
clinical trials in the management of insulin resistance and
type 2 diabetes [6–8]. However, these agonists can also
produce moderate to serious side eﬀects such as edema,
weight gain, congestive heart failure, and hepatotoxicity
[9, 10]. Thus, the development of drugs of dual or pan
PPAR modulators with less side eﬀects is desirable for
the management of obesity-related diabetes and dyslipi-
demia.
Cinnamon is the bark of Cinnamoni cassiae and has
been used as traditional folk herbs to treat inﬂammation
for thousands of years in Asia. It is also used in food
industry as antioxidant and spicy agent. In recent years,
several studies have reported that cinnamon extract has
antidiabetic eﬀect on db/db mice and type 2 diabetic
patients [11, 12]. Talpur et al. showed that cinnamon
oils can improve insulin sensitivity [13]a n dR o ﬀey et al.
reported that cinnamon water extract (CE) increases glucose
uptake in 3T3-L1 adipocyte [14]. However, the separated2 PPAR Research
compounds derived from cinnamon displayed little insulin-
like or insulin-enhancing activity [15]. In this report, we
demonstrate that cinnamon water extract can elevate the
expressionofbothPPARγ,αandtheirtargetgenesin3T3-L1
adipocyte possibly through stimulation of the transactivities
of both full length and LBD of PPARγ and PPARα.I nv i v o
study reveals that cinnamon water extract improves insulin
resistance and lipid metabolism in both high-calorie diet-
induced obesity (DIO) mice and db/db mice.
2. MATERIALS AND METHODS
2.1. Materials
Dexamethasone (DEX), 3-isobutyl-1-methylxanthine, insu-
lin, oil red O, troglitazone, and WY-14643 were purchased
fromSigma(St.Louis,Mo).Cinnamonpowderwasobtained
from Shanghai Traditional Chinese Herbs Pharmacy Co.
(Shanghai, China). The power (10g) was extracted in
(100mL) double distilled water with revolving evaporator in
vacuum state using vacuum pump till the volume of water
reduced to 50mL. The supernatant was then ﬁltered through
Whatman paper no. 1 to obtain the cinnamon water extract.
The ﬁnal concentration was 0.2g/mL.
2.2. QuantitativeRT-PCR
TotalRNAextractedfrom3T3-L1adipocyteormousetissues
was reverse transcribed into ﬁrst strand cDNA with random
hexamer primers using a cDNA synthesis kit (Promega,
Madison, Wis). The gene expression levels were analyzed
by quantitative real-time RT-PCR conducted with the ABI
7500 (Applied Biosystems, Foster City, Calif). After an initial
incubation for 2 minutes at 50
◦C, the cDNA was denatured
at 95
◦C for 10 minutes followed by 40 cycles of PCR (95
◦C,
15 seconds, 60
◦C, 60 seconds). All results were obtained in at
least three independent experiments. The mRNA levels of all
genes were normalized using β-actin as an internal control.
2.3. Luciferaseactivityassays
The plasmid construction and transfection were carried out
as described previously [16]. Brieﬂy, 293T cells obtained
from ATCC were cultured in DMEM with 10% FBS.
Transfection solution was added to 293T cells overnight,
then CE and PPAR ligands were added into fresh media and
the cells were harvested for the determination of luciferase
activity 24 hours later. The luciferase reporter assays were
carried out using the Dual-Luciferase Reporter Assay System
(Promega, Madison, Wis) and the transfection eﬃciencies
werenormalizedbyrenillaluciferaseactivity.Alltransfection
experiments were performed in duplicate and repeated at
least three times independently.
2.4. 3T3-L1adipocytedifferentiationand
oilredOstaining
3T3-L1 cells were purchased from American Type Culture
Collection (Va, USA) and maintained in DMEM contain-
ing 10% FBS. To induce diﬀerentiation, two days after
conﬂuence, preadipocytes (designated day 0) were cultured
in diﬀerentiation medium (DM, containing 10% FBS plus
1μg/mL insulin, 0.5μM dexamethasone, 0.5mM IBMX) or
DM + CE at indicated concentrations for 2 days, then
switched to post DM containing 10% FBS and 1μg/mL
insulin. The medium was changed every 2 days. Oil red O
staining was performed on day 5. Brieﬂy, cells were washed
twice with PBS and ﬁxed with 7.5% formaldehyde for 15
minutes. After twice washing with PBS, cells were stained
for at least 1 hour in freshly diluted oil red O solution
in 37
◦C. Cells were photographed using a phase-contrast
Olympus IX70 (Tokyo, Japan) microscope in combination
with a MicroFire digital camera at 200 magniﬁcations.
2.5. Westernblotanalysis
Cells were homogenized in 2X SDS sample buﬀer (Invit-
rogen, Carlsbad, Calif) and boiled for 5 minutes. 10μgo f
protein was separated by 10% SDS-PAGE and transferred to
PVDFmembrane,blockedfor1houratroomtemperaturein
5% nonfat dry milk/PBS-T. PPARγ (Upstate, Charlottesville,
Va) and β-actin antibodies (Sigma, St. Louis, Mo) were
added to 2% BSA in PBS-T and incubated with the
membrane for 1 hour at room temperature. The membrane
was then washed 3 times with PBS-T for 10 minutes each,
incubated with HRP conjugated secondary antibody (Santa
Cruz,Calif)for30minutesatroomtemperature,andwashed
3 times with PBS-T for 30 minutes totally. The signals were
detected by ECL Plus Western Blotting Detection System
according to the manufacturer’s speciﬁcations (Amersham,
Little Chalfont Buckinghamshire, England).
2.6. Invivoanimalstudy
Female C57BL/6J mice were purchased from the SLAC
Laboratory (Shanghai, China) and db/db (C57BL BKS cg-
M+/+ lepr
−/−)m i c ew e r ep u r c h a s e df r o mJ a c k s o nL a b( M e ,
USA)andbredinhouse.Allmicewerekeptundercontrolled
temperature (22-23
◦C) and on a 12-hour light/dark cycle.
C57BL/6J mice were placed on a high-fat diet (60% of
calories derived from fat, Research Diets, New Brunswick,
NJ, D12492) for induction of obesity, while control mice
were placed on the equivalent chow diet (10% of calories
derived from fat, Research Diets, D12450B). DIO mice with
similar body weight and db/db mice with similar fasted
glucose level were used in the experiments. Mice were
gavaged with CE (correspond to 400mg cinnamon powder
kg • day•) or water only as control at 2PM each day in a
vehicle of water. All animal protocols used in this study were
preapproved by Shanghai Institutes for Biological Sciences of
CAS for animal studies.
2.7. Intraperitonealglucosetolerancetest(IPGTT)
C57BL/6J mice were fasted overnight on day 21 and db/db
mice were fasted for 6 hours on day 15 prior to the blood
samples were collected from tail vein for the determination
of baseline glucose values (t=0 minute) before the injection
of glucose (intraperitoneal injection 2g/kg). AdditionalXiaoyan Sheng et al. 3
blood samples were collected with regular intervals (t =
15,30,60,90,120, and 240 minutes) for glucose measure-
ment. Blood glucose levels were evaluated with a glucose
analyzer (TheraSense, Abbott Park, Ill).
2.8. Serumchemistryanalysis
Serum triglyceride (TG), total cholesterol (TC), HDL-C
and LDL-C, AST, and ALT were examined using a Hitachi
7020 Automatic Analyzer in 100μl of heart blood serum.
FFA was analyzed with an Ultrospec 2100 Pro UV/Visible
spectrophotometer (Amersham, Little Chalfont Bucking-
hamshire, England) with kits fromJiancheng Bioengineering
Ins (Nanjing, China). Serum insulin was measured by ELISA
kit (Linco Research, Mo, USA).
2.9. Statisticalanalysis
The results were represented as the mean ± S E .D a t aw e r e
analyzed by the statistical analysis system (SAS) program.
Comparison between the control and treated groups was
made by ANOVA variance analysis and their signiﬁcance was
established by Student’s t-test. Diﬀerences of P<. 05 were
considered statistically signiﬁcant.
3. RESULTS
3.1. CEimproveshyperlipidemiaandliverfunction
inDIOC57BL/6Janddb/dbmice
After 5-month induction with high-fat diet, the body weight
of C57BL/6J mice was increased to 150% and the serum
TG, LDL, AST, and ALT were greatly elevated compared to
normal food fed mice as indicated in Table 1. Three weeks
after gavage treatment with CE, equivalent to cinnamon
400mg/kg • day, serum FFA and LDL-c were signiﬁcantly
reduced (see Table 1). However, the body weight and food
intake remained unchanged (data not shown). Since high-fat
diet can usually impair the liver function and elevate AST
and ALT levels, we examined AST and ALT in CE-treated
DIO mice and found that CE intervention can eﬀectively
improve liver function as evidenced by signiﬁcantly reduced
AST and ALT levels in DIO mice (see Table 1). To testify
whether CE has similar eﬀects on db/db mice, 11 weeks old
db/db mice were treated with CE for 2 weeks. The serum
FFA of db/db mice was decreased markedly after 2 weeks of
CE treatment (data not shown), suggesting that CE can also
improve dyslipidemia in genetically defective obese mice.
3.2. CEreduceshyperglycemiaandimprovesglucose
toleranceinbothDIOmiceanddb/dbmice
To evaluate whether CE has any inﬂuence on glucose toler-
ance, IPGTT determination was carried out for overnight
fasted DIO mice at 0 minute, 15 minutes, 30 minutes,
60 minutes, and 120 minutes following 2g/kg glucose
intraperitoneal injection DIO mice developed severe insulin
resistance after 5 months high-fat food inductions, and
serum insulin level increased nearly 3 times compared to
Table 1: Eﬀects of CE on serum chemistry of DIO mice. NFC:
normal-fat diet control; HFC: high-fat diet control. The data are
representedasmean±SE,n = 5foreachgroup .∗P<. 05, ∗∗P<. 01
compared to HFC.
Serum chemistry NFC (H2O) HFC (H2O) HF + CE
(400mg/kg)
FFA (mmol/L) 1.31 ±0.06 1.67 ±0.15 1.08 ±0.08
∗∗
TC (mmol/L) 1.46 ±0.15 2.39 ±0.33 2.22 ±0.31
TG (mmol/L) 0.13 ±0.08 0.14 ±0.03 0.11 ±0.07
HDL (mmol/L) 1.14 ±0.14 2.04 ±0.27 2.04 ±0.24
LDL (mmol/L) 0.20 ±0.03 0.26 ±0.07 0.16 ±0.08
∗
Insulin (ng/mL) 0.49 ±0.07 1.44 ±0.75 1.09 ±0.25
AST (IU/L) 164.6 ±83.7 330.8 ±152.4 128.3±27.4
∗∗
ALT (IU/L) 23.28 ±10.88 6 .43 ±49.5 60.31 ±15.99
the control mice on normal diet (see Table 1). Three weeks
of CE treatment not only reduced fasted glucose level but
also improved glucose tolerance markedly (see Figures 1(a)
and 1(b)). The serum insulin level was decreased after CE
treatment (Table 1). Similar eﬀects were observed on db/db
mice as demonstrated in Figures 1(c) and 1(d). Our results
suggestedthatCEiscapableofimprovinginsulinsensitivities
in both high-fat diet-induced diabetic mice and db/db mice.
3.3. CEpromotes3T3-L1preadipocytedifferentiation
In order to understand the underlying mechanism of CE
in hypolipidemia and hypoglycemia, we used preadipocyte
3T3-L1 as an in vitro system to study the inﬂuence of CE on
preadipocyte diﬀerentiation. To analyze the eﬀects of CE on
3T3-L1 preadipocyte diﬀerentiation, CE was added to 3T3-
L1 cells during diﬀerentiation induction in diﬀerentiation
medium (DM). On day 5, we found that the number and
the volume of adipocytes were increased in CE-treated cells
compared to those induced by DM only indicating that
CE may promote 3T3-L1 preadipocyte diﬀerentiation (see
Figures 2(a), 2(b), 2(c), and 2(d)). However, the number and
sizeoftheadipocytesinWATinCE-treatedDIOmiceremain
unchanged (Figures 2(e) and 2(f)).
3.4. CEenhancesgeneexpressionofPPARγ,
PPARα,andthetargetgenes
Since PPARγ and PPARα play essential roles in adipocyte
diﬀerentiation and lipid homeostasis, we further studied
whether CE increases 3T3-L1 adipocyte diﬀerentiation
through the activation of PPARs. The above-mentioned CE-
treated cells were collected to determine the expression levels
of PPARγ,P P A R α and their target genes such as CD36, FAS,
LPL, GLUT4, and ACO. The results showed that CE not only
elevated the expression of PPARγ and its target genes CD36,
LPL, FAS, and GLUT4 signiﬁcantly (see Figure 3(a)), but
also increased the expression of PPARα and its target gene
ACO markedly (Figure 3(b)). Further examination at the
protein level of PPARγ conﬁrmed that CE can signiﬁcantly4 PPAR Research
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Figure 1: CE reduced the fasted blood glucose level and improved glucose tolerance in DIO anddb/dbmice. Mice were administered vehicle
alone, or CE (equivalent to 400mg cinnamon powder kg • day•)f o r3w e e k s( D I O )o r2w e e k s( db/db). The blood glucose levels were
measured in tail vein and the basal glucose levels were shown at 0 minute. (a) DIO C57BL/6J mice were fasted overnight and glucose levels
were measured at 9:00 am at the end treatment. NF: normal food fed mice; HF: high-fat food-induced mice; CE: cinnamon water extract; (b)
fasted DIO mice were intraperitoneally injected with 2g glucose • kg
− body weight and glucose tolerance determined at the time indicated;
(c) db/db Mice were fasted for 6 hours and the fasted blood glucose was measured. CONT: vehicle; (d) glucose tolerance was determined
following 2g glucose•kg
−1 body weight intraperitoneal injection in db/dbmice. The data are presented as mean ± SE, n = 5f o re a c hgr o u p .
(b) ∗P<. 05 versus HF group or (d) vehicle control (cont).
increase the PPARγ protein level in 3T3-L1 adipocyte during
diﬀerentiation (Figure 3(c)).
3.5. CEincreasestransactivitiesofPPARγ andPPARα
To test whether CE could increase the transactivities of
PPARγ and PPARα, full-length PPARγ and PPARα expres-
sion plasmids were transfected into 293T cells for the
reporter gene assays. We found that CE increased the
transactivities of both PPARγ (P<. 05) and PPARα (P<. 01)
in a dose-dependent manner (see Figures 4(a) and 4(b)).
In order to exclude the endogenous factors, ligand-binding
domains (LBD) of PPARγ and PPARα were used to evaluate
the reporter gene activities. Results showed that the LBD
activities of both PPARγ and PPARα were also elevated (P<
.05) (see Figures 4(c) and 4(d)). These data suggest that CE
is a dual activator of both PPARγ and PPARα.
3.6. CEtreatmentelevatestheexpressionof
PPARγ/αandtargetgenesinDIOmice
To verify whether CE treatment has any eﬀect at the
transcriptional level in related tissues in DIO mice, we
examined the gene expression of PPARs and their target
genesinwhiteadipocytetissue(WAT)andliverofCE-treated
DIO mice and controls. PPARγ, dominantly expressed inXiaoyan Sheng et al. 5
(a) (b)
(c) (d)
(e) (f)
Figure 2: CE promoted 3T3-L1 adipocyte diﬀerentiation. 3T3-L1
cells were stained with oil red O at day 5. (a) Undiﬀerentiated
control cells; (b) DM (insulin 10μg/mL, dexam: 1μM, IBMX:
0.5mM)-induced diﬀerentiated cells; (c) DM-induced diﬀerenti-
ated cells + CE 0.2mg/mL; (d) DM-induced diﬀerentiated cells +
CE 0.6mg/mL; (e) HE staining of WAT from high-fat diet control
(HFC) mice; (f) HE staining of WAT from HF + CE-treated mice.
WAT, was slightly elevated, but its target genes, LPL and
CD36, were increased markedly (see Figure 5(a)). PPARα
and its target gene ACO, mainly expressed in liver, were also
elevated signiﬁcantly in CE-treated mice compared with the
controls (Figure 5(b)).In vivo data further suggestedthat CE
is a dual activator of PPARγ and PPARα.
4. DISCUSSION
There are several studies reported that cinnamon has anti-
hyperglycemic and anti-hyperlipidemic eﬀects on diabetic
animals and type 2 diabetic patients. However, the under-
lying mechanisms remain illusive. Here, we use early type
2 diabetic DIO mice, and severe type 2 diabetic db/db
mice, as in vivo models, and 3T3-L1 adipocyte as in
vitro diﬀerentiation model to study the eﬀects of CE on
lipid and glucose metabolism and their possible underlying
mechanisms.
In vitro studies demonstrate that CE acts like a dual
activator to PPARγ/α based on three evidences: ﬁrst, oil
red O staining showed that CE stimulated diﬀerentiation of
3T3-L1 cells from preadipocytes into adipocytes. Secondly,
CE treatment not only increased mRNA levels of PPARγ
and PPARα but their target genes CD36, LPL, FAS, GLUT4,
and ACO increased up to thousands of folds during 3T3-
L1 diﬀerentiation compared to those untreated cells. Finally,
the reporter gene assay conﬁrmed that CE increased trans-
activities of both full length and LBD of PPARγ and PPARα
signiﬁcantly.
Diet-induced obese mouse is an early type 2 diabetic
model. After 5 months induction with 60% calories fat
diet, the body weight and fat weight of C57BL/6J mice
were increased remarkably, and the mice developed insulin
resistance and hyperinsulinemia fatty liver, and impairment
of liver function which are often observed in early type 2
diabetes [17, 18]. Our results showed that after 3 weeks gav-
age with CE, both IPGTT and hyperinsulinemia improved
markedly compared to the untreated ones. Although both
increased insulin secretion and reduced insulin resistance
can improve IPGTT, lowered insulin level and improved
IPGTT in our study are beneﬁcial to the reduction of insulin
resistance. Serum contents of FFA, which impair insulin
secretion and induce beta-cell lipotoxicity [19] and inhibit
insulin-stimulated glucose uptake into muscle [20], were
also reduced notably in DIO mice. The gene expression of
PPARγ and its target genes CD36, LDL in white fat tissue,
and PPARα and its target gene ACO in liver were also
elevated in CE-treated DIO mice indicating that CE may
act as a dual activator of PPARγ and PPARα resulting in
improved insulin resistance and lowered serum lipids. In
genetic diabetic model db/db mice, CE played similar roles
in hypoglycemia and hypolipidemia.
Type 2 diabetic patients are at a higher risk for cardio-
vascular disease (CVD) than nondiabetic individuals [21].
Current evidence overwhelmingly conﬁrms the role of low-
density lipoprotein cholesterol (LDL-c) in the pathogenesis
of atherosclerosis and the risk of CVD, lowering LDL-c is
associated with a reduction in risk of CVD [22, 23]. Our
study shows that CE reduces serum LDL-c to normal level
in DIO mice, suggesting that CE may be beneﬁcial to CVD.
Another ﬁnding may be noted in this study is that CE
treatment improved impaired liver function in DIO mice.
Elevated serum levels of AST and the ratio of AST/ALT
usually indicate hepatocyte damage [24], and the most
common presentation is elevated liver enzymes AST and
ALT in fatty liver [25]. In DIO mice, serum AST and
ALT were increased notably, but 3 weeks of CE treatment
signiﬁcantly decreased serum AST level and the ratio of
AST/ALT, suggesting that CE may play an important role in
improving liver function.
A meta-analysis based on ﬁve randomized clinical trials
have shown that the use of cinnamon does not appear to
improve A1C, FBG, or lipid parameters in patients with
type 1 or type 2 diabetes [26]. Our preliminary study also
showed no eﬀect on DIO or db/db mice when cinnamon
powder was used without water extraction. In present
study, cinnamon water extract exhibited hypoglycemic and
hypolipidemic eﬀects on both DIO and db/db mice. This
is in agreement with the results reported by Mang et al.
demonstrating that the aqueous cinnamon extract seemed
to have a moderate eﬀect in reducing fasting plasma glucose
concentrations in diabetic patients with poor glycaemic
control [27]. The water extraction may have enriched the6 PPAR Research
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Figure 3: CE increased expression of PPARs and their target genes in diﬀerentiated 3T3-L1 cells. 3T3-L1 cells were diﬀerentiated in 24-well
plate and CE 0.6mg/mL was added at the same time. On day 5, cells were collected and total RNA was extracted and reversely transcribed
into the ﬁrst strand cDNA with random hexamer primers using cDNA synthesis kit. The gene expression levels were analyzed by quantitative
real-time RT-PCR. (a) PPARγ and its target genes; (b) PPARα and its target gene; (c) Western blot of CE-treated 3T3-L1 diﬀerentiated cells
from day 5. 1: Control; 2: DM; 3: Rosiglitazone 1μM; 4: DM + CE 0.2mg/mL; 5: DM + CE 0.6mg/mL. For real-time PCR, the results
were repeated in at least 3 independent experiments, and β-actin mRNA was used as an internal control. Data are presented as mean ± SE.
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Figure 4: CE activated transactivities of PPARγ and PPARα. Full-length PPARγ or PPARα was cotransfected with PPRE-J3-TK-Luc reporter
construct to 293T cell and treated with CE (0.2mg/mL, 0.6mg/mL), 1 μM of troglitazone or WY-14643 for 24 hours as positive controls.
Rellina luc was used as a transfection eﬃciency control and the relative luciferase activities were measured against renilla luciferase activities.
For LBD activity assay, pMCX-GAL4-LBD of PPARγ or α expression constructs were cotransfected with USAG ×4-TK-Luc into 293T using
the same protocol as described above. The empty vectors were used as control. (a) Full-length PPARγ.( b )F u l l - l e n g t hP P A R α. (c) LBD
PPARγ. (d) LBD PPARα. The results represent three independent experiments. Data are presented as mean ± SE. ∗P<. 05, ∗∗P<. 01. Tro:
troglitazone; WY: WY14643.
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Figure 5: CE promoted gene expression of PPARγ,P P A R α and their target genes in WAT and liver from DIO mice: (a) real-time PCR of
PPARγ and its target gene expression in white fat tissue; (b) real-time PCR of PPARα and its target gene expression in liver. HF: high-fat diet;
n = 5; data are presented as mean ± SE. ∗P<. 05 compared to control.8 PPAR Research
active components of cinnamon to activate both PPARα and
PPARγ which are beneﬁcial to lipid and glucose metabolism.
Thus, preparation of cinnamon such as water extraction may
be considered when designing new clinical trials.
In conclusion, our study demonstrated that CE had
several beneﬁcial eﬀects on type 2 diabetes possibly through
the activation of both PPARγ and PPARα resulting in
improved insulin resistance, lowered blood glucose, and
serum lipid level without weight gain and the structure
change of the white adipose tissue. In addition, CE improved
the liver function of obese mice. CE may have potential
use in management of obesity-related type 2 diabetes and
hyperlipidemia.
ABBREVIATIONS
ACO: Acyl-CoA oxidase
FAS: Fatty acid synthase
Glut4: Glucose transporting protein 4
LPL: Lipoprotein lipase
CD36: Fatty acid transporter
DIO: Diet-induced obesity
FFA: Free fatty acids
IPGTT: Intraperitoneal glucose tolerance test
HDL-C: High-density lipoprotein cholesterol
LDL-C: Low-density lipoprotein cholesterol
PPAR: Peroxisome proliferator-activated receptor
TC: Total cholesterol
TG: Triglyceride
TZD: Thiazolidinediones
GLU: Glucose
AST: Aspartate aminotransferase
ALT: Alanine aminotransferase
CE: Cinnamon water extract
LBD: Ligand-binding domain
DM: Diﬀerentiated medium.
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